Amgen Inc. Deferred Income Tax Expense (Benefit)
Amgen Inc. (AMGN) reported Deferred Income Tax Expense (Benefit) of -$700.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-13
- Amgen Inc. deferred income tax expense (benefit) for the quarter ending 2018-12-31 was -$69.00M.
- Amgen Inc. deferred income tax expense (benefit) for the quarter ending 2018-09-30 was -$180.00M.
- Amgen Inc. deferred income tax expense (benefit) for the quarter ending 2018-06-30 was -$42.00M.
- Amgen Inc. deferred income tax expense (benefit) for the quarter ending 2018-03-31 was -$72.00M.
- Amgen Inc. deferred income tax expense (benefit) for fiscal 2025 was -$700.00M.
- Amgen Inc. deferred income tax expense (benefit) for fiscal 2024 was -$1.24B.
- Amgen Inc. deferred income tax expense (benefit) for fiscal 2023 was -$1.22B.
- Amgen Inc. deferred income tax expense (benefit) for fiscal 2022 was -$1.27B.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -$700.00M 10-K · filed 2026-02-13 | ||||
| 2024-12-31 | -$1.24B 10-K · filed 2026-02-13 | ||||
| 2023-12-31 | -$1.22B 10-K · filed 2026-02-13 | ||||
| 2022-12-31 | -$1.27B 10-K · filed 2025-02-14 | ||||
| 2021-12-31 | -$434.00M 10-K · filed 2024-02-14 | ||||
| 2020-12-31 | -$363.00M 10-K · filed 2023-02-09 | ||||
| 2019-12-31 | -$304.00M 10-K · filed 2022-02-16 | ||||
| 2018-12-31 | -$69.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-09 | -$249.00M derived: sum of 2 quarters · filed 2021-02-09 | -$291.00M derived: sum of 3 quarters · filed 2021-02-09 | -$363.00M 10-K · filed 2021-02-09 | |
| 2018-09-30 | -$180.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | -$222.00M derived: sum of 2 quarters · filed 2018-10-31 | -$294.00M 10-Q · filed 2018-10-31 | -$1.19B derived: sum of 4 quarters · filed 2020-02-12 | |
| 2018-06-30 | -$42.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-27 | -$114.00M 10-Q · filed 2018-07-27 | -$1.01B derived: sum of 3 quarters · filed 2020-02-12 | -$1.21B derived: sum of 4 quarters · filed 2020-02-12 | |
| 2018-03-31 | -$72.00M 10-Q · filed 2018-04-25 | -$970.00M derived: sum of 2 quarters · filed 2020-02-12 | -$1.17B derived: sum of 3 quarters · filed 2020-02-12 | -$1.27B derived: sum of 4 quarters · filed 2020-02-12 | |
| 2017-12-31 | -$898.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | -$1.10B derived: sum of 2 quarters · filed 2020-02-12 | -$1.20B derived: sum of 3 quarters · filed 2020-02-12 | -$1.28B 10-K · filed 2020-02-12 | |
| 2017-09-30 | -$199.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | -$302.00M derived: sum of 2 quarters · filed 2018-10-31 | -$379.00M 10-Q · filed 2018-10-31 | -$243.00M derived: sum of 4 quarters · filed 2019-02-13 | |
| 2017-06-30 | -$103.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-27 | -$180.00M 10-Q · filed 2018-07-27 | -$44.00M derived: sum of 3 quarters · filed 2019-02-13 | -$209.00M derived: sum of 4 quarters · filed 2019-02-13 | |
| 2017-03-31 | -$77.00M 10-Q · filed 2018-04-25 | $59.00M derived: sum of 2 quarters · filed 2019-02-13 | -$106.00M derived: sum of 3 quarters · filed 2019-02-13 | $207.00M derived: sum of 4 quarters · filed 2019-02-13 | |
| 2016-12-31 | $136.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | -$29.00M derived: sum of 2 quarters · filed 2019-02-13 | $284.00M derived: sum of 3 quarters · filed 2019-02-13 | $216.00M 10-K · filed 2019-02-13 | |
| 2016-09-30 | -$165.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-26 | $148.00M derived: sum of 2 quarters · filed 2017-10-26 | $80.00M 10-Q · filed 2017-10-26 | -$71.00M derived: sum of 4 quarters · filed 2018-02-13 | |
| 2016-06-30 | $313.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-26 | $245.00M 10-Q · filed 2017-07-26 | $94.00M derived: sum of 3 quarters · filed 2018-02-13 | -$31.00M derived: sum of 4 quarters · filed 2018-02-13 | |
| 2016-03-31 | -$68.00M 10-Q · filed 2017-04-27 | -$219.00M derived: sum of 2 quarters · filed 2018-02-13 | -$344.00M derived: sum of 3 quarters · filed 2018-02-13 | -$425.00M derived: sum of 4 quarters · filed 2018-02-13 | |
| 2015-12-31 | -$151.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | -$276.00M derived: sum of 2 quarters · filed 2018-02-13 | -$357.00M derived: sum of 3 quarters · filed 2018-02-13 | -$402.00M 10-K · filed 2018-02-13 | |
| 2015-09-30 | -$125.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-28 | -$206.00M derived: sum of 2 quarters · filed 2016-10-28 | -$251.00M 10-Q · filed 2016-10-28 | -$623.00M derived: sum of 4 quarters · filed 2017-02-14 | |
| 2015-06-30 | -$81.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-29 | -$126.00M 10-Q · filed 2016-07-29 | -$498.00M derived: sum of 3 quarters · filed 2017-02-14 | -$310.00M derived: sum of 4 quarters · filed 2017-02-14 | |
| 2015-03-31 | -$45.00M 10-Q · filed 2016-05-02 | -$417.00M derived: sum of 2 quarters · filed 2017-02-14 | -$229.00M derived: sum of 3 quarters · filed 2017-02-14 | ||
| 2014-12-31 | -$372.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | -$184.00M derived: sum of 2 quarters · filed 2017-02-14 | -$76.00M 10-K · filed 2017-02-14 | ||
| 2014-09-30 | $188.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | $296.00M 10-Q · filed 2015-11-02 | |||
| 2014-06-30 | $108.00M 10-Q · filed 2015-08-05 | ||||
| 2013-12-31 | -$133.00M derived: 8-K 12 month − 10-Q 9 month · filed 2016-10-31 | -$87.00M 8-K · filed 2016-10-31 | |||
| 2013-09-30 | $46.00M 10-Q · filed 2014-10-29 | ||||
| 2012-12-31 | $21.00M 10-K · filed 2015-02-19 | ||||
| 2011-12-31 | -$286.00M 10-K · filed 2014-02-24 | -$357.00M 10-K · filed 2012-02-29 | |||
| 2010-12-31 | -$135.00M 10-K · filed 2013-02-27 | -$151.00M 10-K · filed 2011-02-25 | |||
| 2009-12-31 | $34.00M 10-K · filed 2012-02-29 | ||||
| 2008-12-31 | -$137.00M 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |